Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHB-121 in Healthy and Chronic Hepatitis B Participants
NCT07884864Phase 1Not yet recruiting
- Sponsor
- AusperBio
- Start
- Oct 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial of AHB-121 in Chronic Hepatitis B (CHB) (2 arms), sponsored by AusperBio. Primary endpoint: Safety indicators at 18 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
AHB-121
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07884864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07884864.